- Datum25.09.2024
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalter
stock3
Thomas May
Moderator
Viatris Inc. Registered Shares o.N.
Verkaufen
Kaufen
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Viatris Inc. Registered Shares o.N. Kurse
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Nasdaq | VK | |||||
| L&S | VK | |||||
| Tradegate | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
0,76 %
Intraday
1,28 %
1 Woche
0,59 %
1 Monat
9,88 %
Seit Jahresbeginn
20,32 %
1 Jahr
-12,31 %
3 Jahre
-43,33 %
5 Jahre
-74,87 %
10 Jahre
Wikifolio
Passender Service zu Viatris Inc. Registered Shares o.N.
Webinar zu Viatris Inc. Registered Shares o.N.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)8,740-13,618
- Jahrestief / Hoch ($)9,925-13,618
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Viatris Inc. Registered Shares o.N.
| Ex-Datum | Fiskaljahr | Dividende | Rendite |
|---|---|---|---|
| - | 2026 (e) | ||
| - | 2025 (e) | ||
| - | 2024 (e) | ||
| 23.08.2024 | 2024 | 0,12 $ | 1,03 % |
| 23.05.2024 | 2024 | 0,12 $ | 1,10 % |
| 08.03.2024 | 2024 | 0,12 $ | 0,97 % |
| 23.05.2023 | 2023 | 0,12 $ | 1,27 % |
| 22.11.2023 | 2023 | 0,12 $ | 1,28 % |
| 23.08.2023 | 2023 | 0,12 $ | 1,08 % |
| 08.03.2023 | 2023 | 0,12 $ | 1,12 % |
| 22.11.2022 | 2022 | 0,12 $ | 1,08 % |
| 23.08.2022 | 2022 | 0,12 $ | 1,16 % |
| 23.05.2022 | 2022 | 0,12 $ | 1,02 % |
| 23.02.2022 | 2022 | 0,12 $ | 0,82 % |
| 21.05.2021 | 2021 | 0,11 $ | 0,71 % |
| 22.11.2021 | 2021 | 0,11 $ | 0,84 % |
| 23.08.2021 | 2021 | 0,11 $ | 0,75 % |
Termine von Viatris Inc. Registered Shares o.N.
- Nov7Viatris Inc. Registered Shares o.N.Q3 2024 Earnings Release
- Mär3Viatris Inc. Registered Shares o.N.Q4 2024 Earnings Release
- Mai12Viatris Inc. Registered Shares o.N.Q1 2025 Earnings Release
Beschreibung
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
